Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 61 to 70 of 400 total matches.
Cabtreo: A Three-Drug Gel for Acne
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
(almost clear).
The Medical Letter ® Vol. 66 (1700) April 15, 2024
60
Table 2. Some Topical Products ...
The FDA has approved Cabtreo (Bausch Health), a gel
containing the retinoid adapalene, the oxidizing agent
benzoyl peroxide, and the antibiotic clindamycin, for
treatment of acne vulgaris in patients ≥12 years old.
Cabtreo is the first three-drug topical formulation to
become available in the US for treatment of acne.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):59-60 doi:10.58347/tml.2024.1700b | Show Introduction Hide Introduction
Gepirone (Exxua) for Depression
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
and no significant
effect on weight.7
The Medical Letter ® Vol. 66 (1705) June 24, 2024
Gepirone prolongs the QT ...
The FDA has approved an oral extended-release
formulation of gepirone (Exxua – Fabre-Kramer), a
selective 5-HT1A receptor agonist, for treatment of
major depressive disorder (MDD) in adults. Gepirone
was originally developed decades ago for treatment
of anxiety and depression, but it was not approved by
the FDA for such use. Gepirone is structurally related
to buspirone, which is FDA-approved for treatment
of anxiety.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):97-9 doi:10.58347/tml.2024.1705a | Show Introduction Hide Introduction
Donanemab (Kisunla) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
of this material is strictly prohibited.
For further information call: 800-211-2769
The Medical Letter ® Vol. 66 ...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be started
in patients with mild cognitive impairment (MCI) or
mild dementia. Donanemab is the third IV amyloid
beta-directed monoclonal antibody to be marketed
in the US. Lecanemab (Leqembi – Biogen/Eisai) was
approved by the FDA in 2023 for the same indication
as donanemab. Aducanumab (Aduhelm – Lilly)
was granted accelerated approval in 2021, but it
was withdrawn from the market...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-31 doi:10.58347/tml.2024.1709a | Show Introduction Hide Introduction
Ensifentrine (Ohtuvayre) for COPD
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
The Medical Letter ® Vol. 66 (1709) August 19, 2024
132
69% of patients in ENHANCE-1 and 55% of those ...
The FDA has approved ensifentrine (Ohtuvayre –
Verona), an inhaled phosphodiesterase (PDE) 3 and
4 inhibitor, for maintenance treatment of chronic
obstructive pulmonary disease (COPD) in adults.
It is the first dual inhibitor of PDE3 and PDE4 to be
approved by the FDA, and the first inhaled drug
with a new mechanism of action to be approved for
treatment of COPD in more than 20 years.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):131-3 doi:10.58347/tml.2024.1709b | Show Introduction Hide Introduction
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
: 260 mg;
>55-85 kg: 390 mg; >85 kg: 520 mg.
The Medical Letter ® Vol. 66 (1715) November 11, 2024 ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4 doi:10.58347/tml.2024.1715d | Show Introduction Hide Introduction
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
. www.fdbhealth.com/drug-pricing-policy. The Medical Letter ® Vol. 66 (1713) October 14, 2024 162 Table 2 ...
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal vaccines are currently available in the
US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and
Prevnar 13 (PCV13) are conjugate vaccines licensed
for use in persons ≥6 weeks old, and Pneumovax 23
(PPSV23) is a pneumococcal polysaccharide vaccine
licensed for use in persons ≥2 years old (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):161-3 doi:10.58347/tml.2024.1713a | Show Introduction Hide Introduction
Xanomeline/Trospium (Cobenfy) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
prohibited.
For further information call: 800-211-2769
The Medical Letter ® Vol. 66 (1715) November 11 ...
The FDA has approved Cobenfy (BMS), an oral
fixed-dose combination of the muscarinic agonist
xanomeline and the peripheral muscarinic antagonist
trospium chloride, for treatment of schizophrenia in
adults. It is the first antipsychotic drug to be approved
in the US for treatment of schizophrenia that does not
block dopamine receptors. This is the first approval
for xanomeline; trospium has been available for many
years for treatment of overactive bladder.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-9 doi:10.58347/tml.2024.1715a | Show Introduction Hide Introduction
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
to delay disease progression in patients with
primary progressive MS.
43
The Medical Letter ® Vol. 63 ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
online
The Medical Letter ® Vol. 64 (1645) March 7, 2022
34
Table 1. Some Nonopioid Analgesics ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
........................................................................... online
The Medical Letter ® Vol. 64 (1651) May 30, 2022
82
Table 1. Dosage and Cost of FDA-Approved ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...